Don't Biopsy Your Prostate Until You Hear This (Part 2)

Don't Biopsy Your Prostate Until You Hear This (Part 2) When it comes to your health, are you blindly following the standard protocol—or taking control of your own decisions? In this episode, Dr. Stephen Petteruti dives into the controversial world of PSA tests, prostate biopsies, and the hidden risks behind conventional recommendations. Are these procedures truly necessary, or is there a better way to approach prostate health? Dr. Stephen challenges the status quo and explores alternative approaches that prioritize proactive health management over fear-driven decisions. Have you or someone you know faced a difficult decision about PSA tests or biopsies? Drop your thoughts in the comments—let’s start the conversation! Tune in to the full episode of Intellectual Medicine Podcast —Don't Biopsy Your Prostate Until You Hear This (Part 2). Key Points: 00:00 Introduction 02:58 Studies made about PSA 07:01 What is “statistically significant” 07:55 The Stockholm study 10:27 Cellular escape 14:38 Biopsies can lead to metastatic process 11:14 Risks of a prostate biopsy 16:51 Clinical diagnosis vs invasive procedures 17:25 Intellectual Medicine’s unique approach 18:52 Vitality first 20:40 Have a conversation about other options Enjoy the podcast? Subscribe and leave a 5-star review on your favorite Platforms. ———————————————————————————————— Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives. Website: www.intellectualmedicine.com LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: https://www.instagram.com/intellectualmedicine YouTube: https://www.youtube.com/@intellectualmedicine Personal Brand: https://drstephenpetteruti.com/ Prostate Information: https://intellectualmedicine.com/prostatecancersupport/ Prostate Consultation: https://intellectualmedicine.com/product/30-minute-prostate-health-consultation-with-dr-stephen-petteruti-copy/ Prostate Supplements: https://intellectualmedicine.com/product-category/prostate-support/ Disclaimer: The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan. #ProstateHealth #MensHealthMatters #CancerAwareness #HealthTips #MedicalMyths #PreventiveHealth #ProstateCare #WellnessMatters #StayInformed #healthpodcast References: C, Jacklin et al. “"More men die with prostate cancer than because of it" - an old adage that still holds true in the 21st century.” Cancer treatment and research communications vol. 26 (2021): 100225. doi:10.1016/j.ctarc.2020.100225 Hamdy, Freddie C et al. “Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.” The New England journal of medicine vol. 388,17 (2023): 1547-1558. doi:10.1056/NEJMoa2214122 Kishan, Amar U, and Patrick A Kupelian. “Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects.” Brachytherapy vol. 14,2 (2015): 148-59. doi:10.1016/j.brachy.2014.11.005 Nead, Kevin T et al. “Association Between Androgen Deprivation Therapy and Risk of Dementia.” JAMA oncology vol. 3,1 (2017): 49-55. doi:10.1001/jamaoncol.2016.3662 Wilt, Timothy J et al. “Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.” The New England journal of medicine vol. 377,2 (2017): 132-142. doi:10.1056/NEJMoa1615869